Active Monitoring vs Surgery vs Radiotherapy: The 15-Year ProtecT Results

What the 15-year results actually showed

After 15 years of follow-up, the ProtecT trial found that men with localized, PSA-detected prostate cancer died of their cancer at similarly low rates whether they were assigned to active monitoring, radical prostatectomy, or radiotherapy. Roughly 97 percent survived their prostate cancer in each group. What separated the arms was not who died but who progressed: monitoring produced more metastasis and more local progression without translating into more deaths over this window.

ProtecT (Prostate Testing for Cancer and Treatment) is one of the few randomized trials that directly compares these three strategies in screen-detected disease. Its 15-year report appeared in the New England Journal of Medicine in 2023. Between 1999 and 2009, the trial randomly assigned 1,643 UK men aged 50 to 69 with clinically localized prostate cancer to active monitoring (545 men), surgery (553), or radiotherapy with neoadjuvant hormone therapy (545). Median follow-up reached 15 years.

The mortality endpoint: flat across all three arms

Death from prostate cancer, the primary endpoint, was uncommon and statistically indistinguishable between groups. There were 45 prostate-cancer deaths in total: 17 (3.1 percent) with active monitoring, 12 (2.2 percent) with prostatectomy, and 16 (2.9 percent) with radiotherapy. The overall comparison was not significant. Death from any cause was also nearly identical, near 21 to 23 percent in each arm, which is a reminder that men of this age face competing causes of death that dwarf the cancer itself.

That flat mortality curve is the headline most readers take away, and it is genuinely important. In this screened, largely low- and intermediate-risk population, deferring radical treatment did not cost men their lives over 15 years. But a trial can report one reassuring endpoint and several sobering ones at the same time, and ProtecT does exactly that.

Where the arms diverged: metastasis and progression

The secondary endpoints tell a different story. Metastasis was about twice as common under active monitoring: 9.4 percent (51 men) versus 4.7 percent (26 men) after surgery and 5.0 percent (27 men) after radiotherapy. Local progression followed the same pattern, roughly 26 percent with monitoring against 10 to 11 percent with radical treatment. More men in the monitoring arm eventually started long-term androgen-deprivation therapy.

Crossover matters for reading these numbers. By 15 years, most men assigned to active monitoring had actually undergone radical treatment at some point as their disease was reclassified or their PSA rose. ProtecT was an intention-to-treat comparison of strategies, not a comparison of men who never treated against men who did. Active monitoring here means a structured plan to intervene when signals change, not indefinite inaction.

How to read a trial where endpoints point different ways

This is the interpretive core of ProtecT, and it generalizes well beyond prostate cancer. When a trial's fatal endpoint is flat but its progression endpoints diverge, three questions help.

Is the fatal endpoint mature enough to trust?

Prostate cancer often kills slowly. Fifteen years is long by trial standards but may still be short relative to the natural history of some tumors in men diagnosed in their fifties. The metastasis gap that opened by year 15 is the kind of signal that can, in principle, widen into a mortality gap with longer follow-up. The current data do not show that, and they may never, but a flat curve at 15 years is a statement about 15 years, not about a lifetime.

What is the cost of the progression that monitoring allows?

Metastatic prostate cancer and the androgen-deprivation therapy used to control it carry real burdens even when they are not fatal: bone disease, fatigue, cardiometabolic effects, and reduced quality of life. A man deciding between strategies is weighing a lower chance of ever needing those treatments against the upfront harms of surgery or radiotherapy.

What are the harms on the other side of the ledger?

The reassurance about survival does not make radical treatment free. Across ProtecT's earlier quality-of-life reports, surgery produced the largest and most durable declines in urinary continence and erectile function, while radiotherapy was more associated with bowel effects. Those tradeoffs are the reason the trial's own authors framed the decision as a balance of benefits and harms rather than a single right answer.

What ProtecT does and does not settle

ProtecT applies to a specific population: men whose cancer was found through PSA screening, most of it low- or intermediate-risk by the standards of the time. It does not speak to high-risk or already-metastatic disease, and its monitoring protocol predates modern tools such as MRI-guided biopsy and genomic classifiers, which today let clinicians select monitoring candidates and detect progression more precisely than ProtecT could. A contemporary active-surveillance program is not identical to ProtecT's active monitoring, and the metastasis gap might look different under tighter surveillance.

The trial's durable lesson is methodological. A single endpoint, even a hard one like death, rarely captures a treatment decision. ProtecT shows that monitoring, surgery, and radiotherapy can look equivalent on survival while differing sharply on metastasis, progression, and side effects, and a reasonable man could rank those tradeoffs in more than one order. This article is educational and is not medical advice; treatment choices for localized prostate cancer should be made with a clinician who knows the individual's risk category, values, and health. The value of a trial like ProtecT is not that it names a winner but that it lays the tradeoffs out clearly enough for that conversation to happen honestly.